PGNY · Progyny, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adj. EBITDA non-GAAP | $62.1M | 2Q 2026 | — |
|
|
|||
| Adjusted Earnings Per Diluted Share non-GAAP | $1.04 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 17.7% | Q2 2026 | — |
|
|
|||
| ART Cycles per Unique Female Utilizer | 0.51 | 2Q 2026 | — |
| Assisted Reproductive Treatment (ART) Cycles | 32,645 | Six Months Ended June 30, 2026 | — |
| Average Members | 7,176,000 | Six Months Ended June 30, 2026 | — |
| Clients | 6,743 | 2Q 2026 | — |
| Female Utilization Rate | 0.49% | 2Q 2026 | — |
| Fertility and family building clients | 604 | Q2 2026 | — |
| Utilization - All Members | 0.85% | Six Months Ended June 30, 2026 | — |
| Utilization - Female Only | 0.71% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PGNY
this stock
Progyny, Inc.
|
$2.02B | +2.3% | +10.4% | 28.6 | 5.8% |
|
UNH
Unitedhealth Group Inc
|
$364.06B | +21.7% | +11.8% | — | 1.7% |
|
CVS
CVS HEALTH Corp
|
$124.26B | +22.4% | +7.8% | 25.6 | 1.5% |
|
ELV
Elevance Health, Inc.
|
$86.82B | +14.2% | +12.5% | 17.7 | 2.6% |
|
CI
Cigna Group
|
$74.66B | +2.7% | +11.2% | 11.7 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PGNY | -6.5% | -17.7% | +23.3% | -15.6% | +2.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -6.9% | -22.1% | +9.6% | -19.5% | -11.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.